Personalized Cancer Treatment Platform using AI-Driven Fusion Protein Technology

A next-generation cancer treatment platform leveraging AI, machine learning, and CRISPR-Cas9 genome-wide screening to create personalized fusion protein-based therapeutics and vaccines, revolutionizing cancer treatment outcomes and patient care.

The original patent disclosed a pharmaceutical composition for cancer treatment comprising a fusion protein and an anticancer agent. However, the limitations of this approach include the lack of personalization, limited understanding of patient-specific genomic profiles, and the inability to adapt to emerging cancer targets. The new inventive concept addresses these limitations by integrating AI-driven analytics, CRISPR-Cas9 genome-wide screening, and real-time monitoring to create a more effective and adaptive cancer treatment platform.

The new inventive concept comprises a system for personalized cancer treatment, including a fusion protein generator, a machine learning module, and a cloud-based analytics platform. The fusion protein generator produces a fusion protein dimer comprising a CD80 protein or fragment and an IL-2 protein or variant. The machine learning module predicts optimal anticancer treatment regimens based on patient-specific genomic profiles. The cloud-based analytics platform integrates genomic data, medical imaging data, and patient-reported outcomes to predict treatment response and resistance. Additionally, the system includes a wearable device for tracking patient biomarkers and a module for generating personalized neoantigen-based cancer vaccines.

The new claims introduce a paradigm shift in cancer treatment by integrating AI, machine learning, and CRISPR-Cas9 genome-wide screening to create a personalized and adaptive treatment platform. The inventive step lies in the combination of these technologies to predict optimal treatment regimens, identify novel cancer targets, and generate personalized neoantigen-based vaccines.

Alternative embodiments of the inventive concept could include the use of different AI algorithms, machine learning models, or CRISPR-Cas9 screening approaches. Variations could also include the integration of additional data sources, such as electronic health records or social media data, to enhance the predictive power of the platform.

The inventive concept has significant commercial potential in the cancer treatment market, with potential applications in personalized medicine, precision oncology, and cancer vaccine development. The target industries include pharmaceutical companies, biotech firms, and healthcare providers, with potential for partnerships and collaborations to accelerate development and commercialization.